Evidence map›Paper›PMID 29530484›Full record

ReviewMatrix biology : journal of the International Society for Matrix Biology2018

Cartilage oligomeric matrix protein: COMPopathies and beyond.

Karen L Posey, Francoise Coustry, Jacqueline T Hecht

Open access · greenAbstract readReview
In one paragraph

Review in Matrix biology : journal of the International Society for Matrix Biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers.

0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

138 citing papers in PubMed, 216 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Molecular Mechanisms of Rotator Cuff Degeneration Identified by Spatial Transcriptomics and Multiplex Immunofluorescence.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2026
    Article
  18. Article
  19. Article
  20. Article

78 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Karen L PoseyMcGovern Medical School, UTHealth, Department of Pediatrics, United States. Electronic address: Karen.Posey@uth.tmc.edu.
Francoise CoustryMcGovern Medical School, UTHealth, Department of Pediatrics, United States.
Jacqueline T HechtMcGovern Medical School, UTHealth, Department of Pediatrics, United States; UTHealth, School of Dentistry, United States.
The University of Texas Health Science Center at Houston · USUniversity of Texas Health Science Center at Dallas · US

Funding

Consequences of Mutant COMP Expression and Therapeutic Approaches in Transgenic MiceR01AR057117 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HECHT, JACQUELINE T, POSEY, KAREN LASHEA · 2010 to 2020
$4.2M
NIAMS NIH HHS R01 AR057117
6 · The paper itself

Abstract

Cartilage oligomeric matrix protein (COMP) is a large pentameric glycoprotein that interacts with multiple extracellular matrix proteins in cartilage and other tissues. While, COMP is known to play a role in collagen secretion and fibrillogenesis, chondrocyte proliferation and mechanical strength of tendons, the complete range of COMP functions remains to be defined. COMPopathies describe pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (MED), two skeletal dysplasias caused by autosomal dominant COMP mutations. The majority of the mutations are in the calcium binding domains and compromise protein folding. COMPopathies are ER storage disorders in which the retention of COMP in the chondrocyte ER stimulates overwhelming cellular stress. The retention causes oxidative and inflammation processes leading to chondrocyte death and loss of long bone growth. In contrast, dysregulation of wild-type COMP expression is found in numerous diseases including: fibrosis, cardiomyopathy and breast and prostate cancers. The most exciting clinical application is the use of COMP as a biomarker for idiopathic pulmonary fibrosis and cartilage degeneration associated osteoarthritis and rheumatoid and, as a prognostic marker for joint injury. The ever expanding roles of COMP in single gene disorders and multifactorial diseases will lead to a better understanding of its functions in ECM and tissue homeostasis towards the goal of developing new therapeutic avenues.

Indexed as

AchondroplasiaBinding SitesBiomarkersCartilage Oligomeric Matrix ProteinExtracellular MatrixHumansMutationOsteochondrodysplasiasPrognosisProtein FoldingBiomarkersCartilage Oligomeric Matrix ProteinTSP5 protein, humanAdaptor proteinBiomarkerCOMPER stressFibrosisPseudoachondroplasia

Identifiers

PMID29530484
PMCPMC6129439
OpenAlexW2793146419

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.